List of Dhivy drug patents
Dhivy is owned by Avion Pharms.
Dhivy contains Carbidopa; Levodopa.
Dhivy has a total of 2 drug patents out of which 0 drug patents have expired.
Dhivy was authorised for market use on 12 November, 2021.
Dhivy is available in tablet;oral dosage forms.
Dhivy can be used as treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
The generics of Dhivy are possible to be released after 28 March, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439613 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(15 years from now) | |
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(15 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 12 November, 2021
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease;...
Dosage: TABLET;ORAL
DHIVY family patents
4
United States
2
Japan
1
Canada
1
Brazil
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic